Mebias Discovery, Inc.
GPCR-targeted drug discovery platform
- Sector
- Biotech
- Headquarters
- PHILADELPHIA, PA
- Founded
- 2015
- Latest Form D
- $631K, Sep 2022
- Total capital
- $3.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $3.6M
- 2 Form D · last Sep 2022
- 49 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 7 pending · first 2020
- Rank in peer group#43 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$631K
- Private capital raisedForm D · SEC · 1st filing$3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#43 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Brett A. ToungeResearcherExecutive Officer, DirectorLinked by 4 patents
- Barbara A. SchilbergDirectorNamed in SEC Form D filings
- Guanghui A. HuDirectorNamed in SEC Form D filings
- Lawrence C. KuoExecutive OfficerNamed in SEC Form D filings
- Michael A. Serrano-WuDirectorNamed in SEC Form D filings
- Shariff S. BayoumyExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 11- PendingSubstituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameUSPTOApplication 18930126
- GrantedSubstituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameUSPTOUS 12,162,837
- PendingSubstituted Ureas and Methods of Making and Using SameUSPTOApplication 17520350
Show all 11 patent records
- Substituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameSep 11, 2025 · Application 18930126Pending
- Substituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameDec 10, 2024 · US 12,162,837Granted
- Substituted Ureas and Methods of Making and Using SameOct 6, 2022 · Application 17520350Pending
- Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using SameMay 3, 2022 · US 11,319,290Granted
- Substituted Ureas and Methods of Making and Using SameDec 14, 2021 · US 11,198,685Granted
- Substituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameNov 17, 2020 · US 10,836,728Granted
- Substituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameApplication PCTUS2018014090Pending
- Compounds, Compositions, And Methods For Treating, Ameliorating, And/or Preventing PainApplication PCTUS2024016274Pending
- Compounds, Compositions, and Methods for Treating, Ameliorating, and/or Preventing PainApplication 63446701Pending
- Substituted 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES And Methods Of Making And Using SameApplication 17709177Pending
- Compounds, Compositions, And Methods For Treating, Ameliorating, And/or Preventing PainApplication 19157249Pending
Related companies, and why
- Allarity Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Lakewood-Amedex, Inc.Similar federal contract value in Biotech · null in contracts
- LB PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- OcuTerra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Ratio Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NANOMEDTRIX LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .